Long Noncoding RNA SBF2-AS1 is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma
Rui Chen,Wenjia Xia,Siwei Wang,Youtao Xu,Zhifei Ma,Weizhang Xu,Erbao Zhang,Jie Wang,Tian Fang,Quan'an Zhang,Gaochao Dong,William Chi-shing Cho,Patrick C. Ma,Giovanni Brandi,Simona Tavolari,Peter Ujhazy,Giulio Metro,Helmut H. Popper,Rong Yin,Mantang Qiu,Lin Xu
DOI: https://doi.org/10.1016/j.omtn.2019.04.004
IF: 10.183
2019-01-01
Molecular Therapy — Nucleic Acids
Abstract:Emerging evidence demonstrates that long non-coding RNAs (lncRNAs) are deeply involved in the development of various cancers. This study identified that SBF2-AS1, an early-stagespecific lncRNA, is critical for the tumorigenesis of lung adenocarcinoma (LUAD). We first analyzed LUAD transcriptome data from The Cancer Genome Atlas and the GEO database by weighted gene co-expression network analysis (WGCNA). Five early LUAD-specific lncRNAs were filtered out, and only SBF2-AS1 was upregulated in LUAD. High expression of SBF2-AS1 indicates poor survival of LUAD, especially the early-stage LUAD, but not lung squamous cell carcinoma. SBF2-AS1 promotes LUAD cells proliferation in vitro, and RNA-sequencing data shows that many cell-cycle-related genes were downregulated after SBF2-AS1 knockdown. Mechanically, SBF2-AS1 could competitively bind with miR-338-3p and miR-362-3p to increase E2F1 expression. Finally, we show that the SBF2-AS1-miR-338-3p/362-3p-E2F1 axis could promote LUAD tumorigenesis in vitro and in vivo. Our study demonstrates that SBF2-AS1, an early-stage-specific lncRNA, promotes LUAD tumorigenesis by sponging miR-338-3p and miR-362-3p and increasing E2F1 expression. The SBF2-AS1-miR-338-3p/362-3p-E2F1 regulatory axis may serve as a prognostic marker and potential therapeutic target for LUAD.